Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 4 4Phase 3 2Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Interventional × drospirenone and ethinyl estradiol combination × Clear all
NCT01603745 2012-05-22

Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome

Catholic University of the Sacred Heart

Phase 1 Unknown
10 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡